Total Asset Turnover
since 2005
Calculation
Celgene Corp., total asset turnover, long-term trends, calculation
| Total asset turnover | = | Net product sales1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|
| Dec 31, 2018 | 0.43 | = | 15,265) | ÷ | 35,480) |
| Dec 31, 2017 | 0.43 | = | 12,973) | ÷ | 30,141) |
| Dec 31, 2016 | 0.40 | = | 11,185) | ÷ | 28,086) |
| Dec 31, 2015 | 0.34 | = | 9,161) | ÷ | 27,053) |
| Dec 31, 2014 | 0.44 | = | 7,564) | ÷ | 17,340) |
| Dec 31, 2013 | 0.48 | = | 6,362) | ÷ | 13,378) |
| Dec 31, 2012 | 0.46 | = | 5,386) | ÷ | 11,734) |
| Dec 31, 2011 | 0.47 | = | 4,700) | ÷ | 10,006) |
| Dec 31, 2010 | 0.34 | = | 3,508) | ÷ | 10,177) |
| Dec 31, 2009 | 0.48 | = | 2,567) | ÷ | 5,389) |
| Dec 31, 2008 | 0.48 | = | 2,138) | ÷ | 4,445) |
| Dec 31, 2007 | 0.36 | = | 1,300) | ÷ | 3,611) |
| Dec 31, 2006 | 0.30 | = | 812) | ÷ | 2,736) |
| Dec 31, 2005 | 0.36 | = | 446) | ÷ | 1,247) |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The analysis of the annual financial data reveals several key trends related to sales, assets, and efficiency ratios over the period from 2005 to 2018.
- Net Product Sales
- There is a clear and consistent upward trend in net product sales, which increased from US$446 million in 2005 to US$15,265 million in 2018. This growth was steady throughout the years, with notable acceleration particularly after 2006 and continuing through to 2018, indicating strong revenue expansion over the period.
- Total Assets
- Total assets also followed an increasing trajectory, rising from US$1,247 million in 2005 to US$35,480 million in 2018. The asset base expanded significantly, particularly in the years 2009 to 2011 and from 2013 onwards. This substantial growth in assets suggests ongoing investment and accumulation of resources to support the expanding operations.
- Total Asset Turnover Ratio
- The total asset turnover ratio, which measures the efficiency in using assets to generate sales, fluctuated over the period but remained within a range of approximately 0.3 to 0.48. It started at 0.36 in 2005, dipped to a low of 0.3 in 2006, and experienced moderate fluctuations thereafter, peaking around 0.48 during several years such as 2008 and 2009. From 2010 onwards, the ratio stabilized around the 0.4 mark, indicating a relatively consistent efficiency in asset utilization despite the substantial growth in both assets and sales.
Overall, the data indicate strong revenue growth backed by significant asset expansion. While asset turnover ratios varied, the company maintained a respectable level of efficiency in converting assets into sales through the years.
Comparison to Competitors
Celgene Corp., total asset turnover, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 0.43 | 0.55 | 0.34 | 0.64 | 0.42 | 0.56 | 0.34 | 0.53 | 0.51 | 0.34 | 0.57 | 0.43 | 0.49 |
| Dec 31, 2017 | 0.43 | 0.40 | 0.27 | 0.62 | 0.39 | 0.51 | 0.37 | 0.49 | 0.46 | 0.31 | 0.67 | 0.37 | 0.70 |
| Dec 31, 2016 | 0.40 | 0.39 | 0.28 | 0.58 | 0.37 | 0.55 | 0.53 | 0.51 | 0.42 | 0.31 | 0.70 | 0.40 | 0.59 |
| Dec 31, 2015 | 0.34 | 0.43 | 0.29 | 0.52 | 0.43 | 0.56 | 0.62 | 0.53 | 0.39 | 0.29 | 0.73 | 0.41 | 0.41 |
| Dec 31, 2014 | 0.44 | 0.72 | 0.28 | 0.47 | 0.54 | 0.53 | 0.71 | 0.57 | 0.43 | 0.29 | 0.73 | 0.39 | 0.25 |
| Dec 31, 2013 | 0.48 | 0.64 | 0.28 | 0.42 | 0.55 | 0.66 | 0.48 | 0.54 | 0.42 | 0.30 | 0.71 | 0.41 | 0.52 |
| Dec 31, 2012 | 0.46 | 0.68 | 0.31 | 0.49 | 0.55 | 0.66 | 0.44 | 0.55 | 0.45 | 0.32 | 0.66 | 0.46 | 0.55 |
| Dec 31, 2011 | 0.47 | — | 0.31 | 0.64 | 0.54 | 0.72 | 0.47 | 0.57 | 0.46 | 0.36 | 0.34 | 0.44 | 0.64 |
| Dec 31, 2010 | 0.34 | — | 0.34 | 0.63 | 0.59 | 0.74 | 0.64 | 0.60 | 0.43 | 0.35 | 0.42 | 0.51 | 0.08 |
| Dec 31, 2009 | 0.48 | — | 0.36 | 0.61 | 0.57 | 0.80 | 0.67 | 0.65 | 0.24 | 0.23 | 0.51 | 0.47 | 0.05 |
| Dec 31, 2008 | 0.48 | — | 0.40 | 0.70 | 0.73 | 0.70 | 0.72 | 0.75 | 0.51 | 0.43 | 0.36 | 0.50 | 0.18 |
| Dec 31, 2007 | 0.36 | — | 0.41 | 0.74 | 0.63 | 0.70 | 0.64 | 0.75 | 0.50 | 0.42 | 0.13 | 0.46 | 0.33 |
| Dec 31, 2006 | 0.30 | — | 0.41 | 0.70 | 0.75 | 0.71 | 0.63 | 0.76 | 0.51 | 0.42 | 0.11 | 0.18 | 0.23 |
| Dec 31, 2005 | 0.36 | — | 0.41 | 0.68 | 0.87 | 0.60 | 0.48 | 0.87 | 0.49 | 0.44 | 0.16 | 0.62 | 0.29 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2018 | 0.43 | 0.45 |
| Dec 31, 2017 | 0.43 | 0.40 |
| Dec 31, 2016 | 0.40 | 0.41 |
| Dec 31, 2015 | 0.34 | 0.42 |
| Dec 31, 2014 | 0.44 | 0.44 |
| Dec 31, 2013 | 0.48 | 0.43 |
| Dec 31, 2012 | 0.46 | 0.45 |
| Dec 31, 2011 | 0.47 | 0.47 |
| Dec 31, 2010 | 0.34 | 0.47 |
| Dec 31, 2009 | 0.48 | 0.39 |
| Dec 31, 2008 | 0.48 | 0.57 |
| Dec 31, 2007 | 0.36 | 0.56 |
| Dec 31, 2006 | 0.30 | 0.54 |
| Dec 31, 2005 | 0.36 | 0.57 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp., total asset turnover, long-term trends, comparison to industry (health care)
| Celgene Corp. | Health Care | |
|---|---|---|
| Dec 31, 2018 | 0.43 | 0.68 |
| Dec 31, 2017 | 0.43 | 0.66 |
| Dec 31, 2016 | 0.40 | 0.67 |
| Dec 31, 2015 | 0.34 | 0.64 |
| Dec 31, 2014 | 0.44 | 0.69 |
| Dec 31, 2013 | 0.48 | 0.67 |
| Dec 31, 2012 | 0.46 | 0.67 |
| Dec 31, 2011 | 0.47 | 0.69 |
| Dec 31, 2010 | 0.34 | 0.68 |
| Dec 31, 2009 | 0.48 | 0.63 |
| Dec 31, 2008 | 0.48 | 0.80 |
| Dec 31, 2007 | 0.36 | 0.77 |
| Dec 31, 2006 | 0.30 | 0.74 |
| Dec 31, 2005 | 0.36 | 0.72 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).